How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference
OBJECTIVE: This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments. RESEARCH DESIGN AND METHODS: The model was tested in a double-blind, randomized clinical tri...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2009-08, Vol.32 (8), p.1411-1417 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1417 |
|---|---|
| container_issue | 8 |
| container_start_page | 1411 |
| container_title | Diabetes care |
| container_volume | 32 |
| creator | Peyrot, Mark Rubin, Richard R |
| description | OBJECTIVE: This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments. RESEARCH DESIGN AND METHODS: The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens. Objective clinical outcomes included changes in glucose and weight control, insulin requirements, incidence of hypoglycemia, and study drug tolerance. At the end of the trial, patients completed the validated PRAM-TSQ questionnaire measuring treatment satisfaction and preference and perceived medication benefits and side effects. RESULTS: Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower medication tolerance, more hypoglycemia). Perceptions of treatment consequences were sensitive and specific to their cognate objective clinical outcomes (no halo effects). Clinical outcomes (especially PPG) accounted for almost half of the effect of the study medication on treatment satisfaction and preference. Treatment satisfaction and preference were strongly related to the perceived benefits/side effects of the study medication, and these perceptions (especially glucose control) mediated most of the association of clinical outcomes with satisfaction and preference. CONCLUSIONS: This model received substantial empirical support. Improvements in objective clinical outcomes accounted for a large part of the association of pramlintide treatment with higher treatment satisfaction and preference. Perceived treatment consequences mediated the effect of objective clinical benefits on satisfaction with and preference for the study medication. |
| doi_str_mv | 10.2337/dc08-2256 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2713611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A206462200</galeid><sourcerecordid>A206462200</sourcerecordid><originalsourceid>FETCH-LOGICAL-f422t-3e442329043ede5b9ca730e8ca956c9d6db657361ee6f0be12848c0dfcb837ac3</originalsourceid><addsrcrecordid>eNptkU9rFDEYh4NY7Fo9-AU0CB6nzb_JTDwopWpbqHhoi8eQSd6MqTPJmswqfnsjuy4VSg6B5Hkffr8EoReUHDPOuxNnSd8w1spHaEUVb5u2Ff1jtCJUqKZVih2ip6XcEUKE6Psn6JAq0ZGedysEF-kX_pCg4JsMZpkhLvjaLKF4Y5eQIv6a8vf3b_Hn5GAKccQOFshziCYuBSePl_1YuT9mosPrDB4yRAvP0IE3U4Hnu_0I3X76eHN20Vx9Ob88O71qvGBsaTgIwThTRHBw0A7Kmo4T6K1RrbTKSTfItuOSAkhPBqCsF70lztuhljGWH6F3W-96M8zgbI2VzaTXOcwm_9bJBP3_TQzf9Jh-atbRqqVV8HonyOnHBsqi79Imx5pZM8YJVaQVFWq20Ggm0CH6VF12hAhVmSL4UI9PGZFCMkZI5Y8f4OtyMAf74MDL-zX2-f99WwXe7ABTrJl8NtGGsucY7VR9x7_cqy3nTdJmzJW5vWaE1iZSUtZJ_gf3CLAl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223019054</pqid></control><display><type>article</type><title>How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Peyrot, Mark ; Rubin, Richard R</creator><creatorcontrib>Peyrot, Mark ; Rubin, Richard R</creatorcontrib><description>OBJECTIVE: This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments. RESEARCH DESIGN AND METHODS: The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens. Objective clinical outcomes included changes in glucose and weight control, insulin requirements, incidence of hypoglycemia, and study drug tolerance. At the end of the trial, patients completed the validated PRAM-TSQ questionnaire measuring treatment satisfaction and preference and perceived medication benefits and side effects. RESULTS: Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower medication tolerance, more hypoglycemia). Perceptions of treatment consequences were sensitive and specific to their cognate objective clinical outcomes (no halo effects). Clinical outcomes (especially PPG) accounted for almost half of the effect of the study medication on treatment satisfaction and preference. Treatment satisfaction and preference were strongly related to the perceived benefits/side effects of the study medication, and these perceptions (especially glucose control) mediated most of the association of clinical outcomes with satisfaction and preference. CONCLUSIONS: This model received substantial empirical support. Improvements in objective clinical outcomes accounted for a large part of the association of pramlintide treatment with higher treatment satisfaction and preference. Perceived treatment consequences mediated the effect of objective clinical benefits on satisfaction with and preference for the study medication.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc08-2256</identifier><identifier>PMID: 19470837</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Age of Onset ; Amyloid - adverse effects ; Amyloid - therapeutic use ; Appetite ; Biological and medical sciences ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Care and treatment ; Clinical outcomes ; Data collection ; Dextrose ; Diabetes ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 1 - psychology ; Diabetes therapy ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Female ; Glucose ; Humans ; Hypoglycemia - epidemiology ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Insulin - adverse effects ; Insulin - therapeutic use ; Islet Amyloid Polypeptide ; Male ; Medical research ; Medical sciences ; Medicine, Experimental ; Metabolic diseases ; Middle Aged ; Miscellaneous ; Models, Psychological ; Original Research ; Patient satisfaction ; Perception ; Personal Satisfaction ; Preferences ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Regression analysis ; Side effects ; Studies ; Type 1 diabetes ; Weight control ; Weight Loss</subject><ispartof>Diabetes care, 2009-08, Vol.32 (8), p.1411-1417</ispartof><rights>2009 INIST-CNRS</rights><rights>COPYRIGHT 2009 American Diabetes Association</rights><rights>Copyright American Diabetes Association Aug 2009</rights><rights>2009 by the American Diabetes Association. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21792327$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19470837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peyrot, Mark</creatorcontrib><creatorcontrib>Rubin, Richard R</creatorcontrib><title>How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE: This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments. RESEARCH DESIGN AND METHODS: The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens. Objective clinical outcomes included changes in glucose and weight control, insulin requirements, incidence of hypoglycemia, and study drug tolerance. At the end of the trial, patients completed the validated PRAM-TSQ questionnaire measuring treatment satisfaction and preference and perceived medication benefits and side effects. RESULTS: Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower medication tolerance, more hypoglycemia). Perceptions of treatment consequences were sensitive and specific to their cognate objective clinical outcomes (no halo effects). Clinical outcomes (especially PPG) accounted for almost half of the effect of the study medication on treatment satisfaction and preference. Treatment satisfaction and preference were strongly related to the perceived benefits/side effects of the study medication, and these perceptions (especially glucose control) mediated most of the association of clinical outcomes with satisfaction and preference. CONCLUSIONS: This model received substantial empirical support. Improvements in objective clinical outcomes accounted for a large part of the association of pramlintide treatment with higher treatment satisfaction and preference. Perceived treatment consequences mediated the effect of objective clinical benefits on satisfaction with and preference for the study medication.</description><subject>Adult</subject><subject>Age of Onset</subject><subject>Amyloid - adverse effects</subject><subject>Amyloid - therapeutic use</subject><subject>Appetite</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Care and treatment</subject><subject>Clinical outcomes</subject><subject>Data collection</subject><subject>Dextrose</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 1 - psychology</subject><subject>Diabetes therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Glucose</subject><subject>Humans</subject><subject>Hypoglycemia - epidemiology</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - adverse effects</subject><subject>Insulin - therapeutic use</subject><subject>Islet Amyloid Polypeptide</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medicine, Experimental</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Models, Psychological</subject><subject>Original Research</subject><subject>Patient satisfaction</subject><subject>Perception</subject><subject>Personal Satisfaction</subject><subject>Preferences</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Regression analysis</subject><subject>Side effects</subject><subject>Studies</subject><subject>Type 1 diabetes</subject><subject>Weight control</subject><subject>Weight Loss</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkU9rFDEYh4NY7Fo9-AU0CB6nzb_JTDwopWpbqHhoi8eQSd6MqTPJmswqfnsjuy4VSg6B5Hkffr8EoReUHDPOuxNnSd8w1spHaEUVb5u2Ff1jtCJUqKZVih2ip6XcEUKE6Psn6JAq0ZGedysEF-kX_pCg4JsMZpkhLvjaLKF4Y5eQIv6a8vf3b_Hn5GAKccQOFshziCYuBSePl_1YuT9mosPrDB4yRAvP0IE3U4Hnu_0I3X76eHN20Vx9Ob88O71qvGBsaTgIwThTRHBw0A7Kmo4T6K1RrbTKSTfItuOSAkhPBqCsF70lztuhljGWH6F3W-96M8zgbI2VzaTXOcwm_9bJBP3_TQzf9Jh-atbRqqVV8HonyOnHBsqi79Imx5pZM8YJVaQVFWq20Ggm0CH6VF12hAhVmSL4UI9PGZFCMkZI5Y8f4OtyMAf74MDL-zX2-f99WwXe7ABTrJl8NtGGsucY7VR9x7_cqy3nTdJmzJW5vWaE1iZSUtZJ_gf3CLAl</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Peyrot, Mark</creator><creator>Rubin, Richard R</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>5PM</scope></search><sort><creationdate>20090801</creationdate><title>How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference</title><author>Peyrot, Mark ; Rubin, Richard R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-f422t-3e442329043ede5b9ca730e8ca956c9d6db657361ee6f0be12848c0dfcb837ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Age of Onset</topic><topic>Amyloid - adverse effects</topic><topic>Amyloid - therapeutic use</topic><topic>Appetite</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Care and treatment</topic><topic>Clinical outcomes</topic><topic>Data collection</topic><topic>Dextrose</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 1 - psychology</topic><topic>Diabetes therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Glucose</topic><topic>Humans</topic><topic>Hypoglycemia - epidemiology</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - adverse effects</topic><topic>Insulin - therapeutic use</topic><topic>Islet Amyloid Polypeptide</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medicine, Experimental</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Models, Psychological</topic><topic>Original Research</topic><topic>Patient satisfaction</topic><topic>Perception</topic><topic>Personal Satisfaction</topic><topic>Preferences</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Regression analysis</topic><topic>Side effects</topic><topic>Studies</topic><topic>Type 1 diabetes</topic><topic>Weight control</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peyrot, Mark</creatorcontrib><creatorcontrib>Rubin, Richard R</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peyrot, Mark</au><au>Rubin, Richard R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>32</volume><issue>8</issue><spage>1411</spage><epage>1417</epage><pages>1411-1417</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE: This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments. RESEARCH DESIGN AND METHODS: The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens. Objective clinical outcomes included changes in glucose and weight control, insulin requirements, incidence of hypoglycemia, and study drug tolerance. At the end of the trial, patients completed the validated PRAM-TSQ questionnaire measuring treatment satisfaction and preference and perceived medication benefits and side effects. RESULTS: Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower medication tolerance, more hypoglycemia). Perceptions of treatment consequences were sensitive and specific to their cognate objective clinical outcomes (no halo effects). Clinical outcomes (especially PPG) accounted for almost half of the effect of the study medication on treatment satisfaction and preference. Treatment satisfaction and preference were strongly related to the perceived benefits/side effects of the study medication, and these perceptions (especially glucose control) mediated most of the association of clinical outcomes with satisfaction and preference. CONCLUSIONS: This model received substantial empirical support. Improvements in objective clinical outcomes accounted for a large part of the association of pramlintide treatment with higher treatment satisfaction and preference. Perceived treatment consequences mediated the effect of objective clinical benefits on satisfaction with and preference for the study medication.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>19470837</pmid><doi>10.2337/dc08-2256</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2009-08, Vol.32 (8), p.1411-1417 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2713611 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Age of Onset Amyloid - adverse effects Amyloid - therapeutic use Appetite Biological and medical sciences Blood Glucose - drug effects Blood Glucose - metabolism Care and treatment Clinical outcomes Data collection Dextrose Diabetes Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - psychology Diabetes therapy Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Female Glucose Humans Hypoglycemia - epidemiology Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin - adverse effects Insulin - therapeutic use Islet Amyloid Polypeptide Male Medical research Medical sciences Medicine, Experimental Metabolic diseases Middle Aged Miscellaneous Models, Psychological Original Research Patient satisfaction Perception Personal Satisfaction Preferences Public health. Hygiene Public health. Hygiene-occupational medicine Regression analysis Side effects Studies Type 1 diabetes Weight control Weight Loss |
| title | How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A33%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Does%20Treatment%20Satisfaction%20Work?:%20Modeling%20determinants%20of%20treatment%20satisfaction%20and%20preference&rft.jtitle=Diabetes%20care&rft.au=Peyrot,%20Mark&rft.date=2009-08-01&rft.volume=32&rft.issue=8&rft.spage=1411&rft.epage=1417&rft.pages=1411-1417&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc08-2256&rft_dat=%3Cgale_pubme%3EA206462200%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223019054&rft_id=info:pmid/19470837&rft_galeid=A206462200&rfr_iscdi=true |